
X
Sanofi’s Kevzara gains first approval in Canada
https://pharmaphorum.com/news/sanofis-kevzara-gains-first-approval-canada/
Celgene continues with focus on autoimmune diseases.
But patents could delay launch for more than a year.
Regulator grants six-month review.
New CEO poaches Luke Miels from rival
Review extended by three months.
Samsung to take on patent thicket surrounding Humira.
Sales of Humira could peak above $18 billion – CEO
Blockbuster likely to face cheap near-copy for first time.